essential cells to remain unharmed. Thus, monoclonal antibodies to GPC3 (and corresponding immunoconjugates) represent a novel therapeutic candidate for treatment of HCC, as well as other cancers associated with the differential expression of GPC3.

**Potential Commercial Applications:**
- Therapeutic antibodies against cancers that overexpress GPC3.
- Therapeutic immunoconjugates or antibody-drug conjugates for killing cancer cells that overexpress GPC3.
- Diagnostics for detecting cancers associated with GPC3 overexpression.
- Specific cancers include hepatocellular cancer (HCC), melanoma, ovarian cancer, thyroid cancer, lung squamous cell carcinoma, Wilms’ tumor, neuroblastoma, hepatoblastoma, and testicular germ-cell tumors.

**Competitive Advantages:**
- Monoclonal antibodies create a level of specificity that can reduce deleterious side-effects.
- Multiple treatment strategies available including the killing of cancer cells with a toxic agent or by inhibiting cell signaling.
- Non-invasive and potentially non-liver toxic alternative to current HCC treatment strategies.

**Development Stage:**
- Pre-clinical.
- In vitro data available.
- In vivo data available (animal).

**Inventors:** Mitchell Ho (NCI) et al.

**Publications:**

**Related Technology:**
- Molecular Biology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize novel antibody or antibody-drug conjugate therapies for the treatment of liver cancer. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov.

Dated: June 14, 2013.

**Richard U. Rodriguez,**
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Eye Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel; NEI Institutional Training Grants and Conference Grants.

**Date:** July 10, 2013.
**Time:** 11:30 a.m. to 2:30 p.m.
**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC 9300, 301–451–2020, hoshawb@mail.nih.gov.


Dated: June 14, 2013.

**Anna Snouffer,**
Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–14815 Filed 6–20–13; 8:45 am]

**BILLING CODE 4140–01–P**